Why, roughly $200MM is cash, revenues from Roche T-DM1 of approx 5% of Billions (eventually hundreds of millions per year at peak) in free cash flow, pipeline, partners, patents, technology platform, plenty of costs available to cut at IMGN. IMGN shareholders respect SGEN management more than IMGN management and would take SGEN stock in the $18-20 range if done soon. SGEN should make a move now IMO.
IMGN is behind the curve no approved products; why should SGEN waste time and money when they are on tract. Just think what happens if IMGN does not get an approval. It would hurt SGEN. Get real no way. Go selll crazy someplace else.